JP2006503874A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006503874A5 JP2006503874A5 JP2004542481A JP2004542481A JP2006503874A5 JP 2006503874 A5 JP2006503874 A5 JP 2006503874A5 JP 2004542481 A JP2004542481 A JP 2004542481A JP 2004542481 A JP2004542481 A JP 2004542481A JP 2006503874 A5 JP2006503874 A5 JP 2006503874A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridylmethyl
- treatment
- formula
- alkyl
- bond
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WHOWNXIYXLWMGJ-UHFFFAOYSA-N 1-(pyridin-4-ylmethyl)phthalazine Chemical class N=1N=CC2=CC=CC=C2C=1CC1=CC=NC=C1 WHOWNXIYXLWMGJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- -1 Cyano, carboxy Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 206010028561 Myeloid metaplasia Diseases 0.000 claims 4
- 241000534944 Thia Species 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 239000003098 androgen Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 3
- 229960004618 prednisone Drugs 0.000 claims 3
- 208000003476 primary myelofibrosis Diseases 0.000 claims 3
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 3
- 229950000578 vatalanib Drugs 0.000 claims 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 229940030486 androgens Drugs 0.000 claims 1
- 238000011254 conventional chemotherapy Methods 0.000 claims 1
- 229960001330 hydroxycarbamide Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41762202P | 2002-10-10 | 2002-10-10 | |
| PCT/EP2003/011214 WO2004033042A1 (en) | 2002-10-10 | 2003-10-09 | Treatment of amm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006503874A JP2006503874A (ja) | 2006-02-02 |
| JP2006503874A5 true JP2006503874A5 (enExample) | 2006-11-24 |
Family
ID=32094051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004542481A Pending JP2006503874A (ja) | 2002-10-10 | 2003-10-09 | Ａｍｍの処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20060148810A1 (enExample) |
| EP (1) | EP1554015A1 (enExample) |
| JP (1) | JP2006503874A (enExample) |
| AU (1) | AU2003271712A1 (enExample) |
| WO (1) | WO2004033042A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101277939A (zh) | 2005-09-09 | 2008-10-01 | 布里斯托尔-迈尔斯斯奎布公司 | 无环ikur抑制剂 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| EP1165085B1 (en) * | 1999-03-30 | 2006-06-14 | Novartis AG | Phthalazine derivatives for treating inflammatory diseases |
-
2003
- 2003-10-09 EP EP03753538A patent/EP1554015A1/en not_active Withdrawn
- 2003-10-09 WO PCT/EP2003/011214 patent/WO2004033042A1/en not_active Ceased
- 2003-10-09 US US10/530,451 patent/US20060148810A1/en not_active Abandoned
- 2003-10-09 AU AU2003271712A patent/AU2003271712A1/en not_active Abandoned
- 2003-10-09 JP JP2004542481A patent/JP2006503874A/ja active Pending
-
2009
- 2009-05-19 US US12/468,151 patent/US20090233939A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6440212B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| KR20200096788A (ko) | 화학치료법-내성 난소암 또는 유방암 치료에서 parp 억제제의 용도 | |
| AU2005246964B2 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| JP2012510444A (ja) | 治療的処置のためのＨｓｐ９０阻害剤 | |
| CA2846272A1 (en) | Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone | |
| JP5340393B2 (ja) | 腎細胞癌の治療のための３，３’，４，４’−テトラヒドロキシ−２，２’−ビピリジン−ｎ，ｎ’−ジオキシド | |
| US20130101680A1 (en) | Radiotherapy enhancer | |
| JP7333560B2 (ja) | 放射線及び／又は化学療法の曝露に関連付けられる副作用を処置及び／又は防止する剤、組成物及びキット | |
| JP7571024B2 (ja) | 抗ｃｃｒ４抗体抵抗性のがんの治療剤 | |
| JP2006503874A5 (enExample) | ||
| RU2430727C2 (ru) | Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний | |
| JP2006502195A5 (enExample) | ||
| RU2353364C2 (ru) | Применение производных 4-пиридилметилфталазина в производстве лекарственного средства для лечения миелодиспластических синдромов | |
| US20090239872A1 (en) | Treatment of mesothelioma | |
| JP2005527552A (ja) | 置換アクリロイルジスタマイシン誘導体および放射線療法を含む腫瘍に対する組合せ治療 | |
| US20040024015A1 (en) | Tumor radiosensitization and /or chemopotentiation using isocoumarin derivatives | |
| JP2006507319A5 (enExample) | ||
| JP2006503874A (ja) | Ａｍｍの処置 | |
| JP2006512360A (ja) | ＶｏｎＨｉｐｐｅｌ−Ｌｉｎｄａｕ病の処置 | |
| JP2008520617A (ja) | 抗癌剤としての銅メルファラン及び銅テガフール | |
| JP2005507410A (ja) | Ｂｃｒ／ａｂｌキナーゼ活性のＡＴＰ競合的阻害剤とチロホスチンアナログとの組合せ剤 |